Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $443.92, signifying a +2.79% move from its prior day's close.
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.75, moving 1.9% from the previous trading session.
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $454.97, signifying a +1.42% move from its prior day's close.
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.59, denoting a -2.36% move from the preceding trading day.
Aquatic Capital Management LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 29,596 shares of the pharmaceutical company's stock, valued at approximately $11,591,000. A number of other institutional investors
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $492.38, representing a -1.36% change from its previous close.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vertex Pharmaceuticals (VRTX) shares are soaring after the company said it achieved "remarkable" results from a new clinical trial.